APLT - Applied Therapeutics - Stock & Dividends
Exchange: USA Stocks • Country: United States • Currency: USD • Type: Common Stock • ISIN: US03828A1016
Applied Therapeutics Inc, a clinical-stage biopharmaceutical company, is dedicated to developing innovative treatments for high unmet medical needs in the United States. The company's pipeline focuses on novel product candidates targeting validated molecular targets, with the goal of improving patient outcomes.
At the forefront of their pipeline is AT-007, also known as govorestat, which has completed phase 3 clinical trials for the treatment of galactosemia in healthy volunteers and adults. Additionally, AT-007 is being studied in pediatric clinical trials for the treatment of galactosemia in children, as well as for treating enzyme sorbitol dehydrogenase and phosphomannomutase enzyme-CDG. This drug candidate has the potential to address a significant unmet medical need, as galactosemia is a rare genetic disorder that affects an individual's ability to metabolize galactose, a sugar found in milk and other dairy products.
Another key product candidate in the pipeline is AT-001, also known as caficrestat, which is currently in phase 3 clinical trials for the treatment of diabetic cardiomyopathy and diabetic peripheral neuropathy. These conditions are common complications of diabetes, and there is a significant need for effective treatments to prevent and manage them.
The company is also exploring AT-003, a preclinical-stage product candidate, for the treatment of diabetic retinopathy, a common complication of diabetes that can lead to blindness if left untreated. By targeting this condition, Applied Therapeutics aims to improve the quality of life for patients with diabetes.
In addition to its robust pipeline, Applied Therapeutics has established an exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. This partnership will enable the company to accelerate the development and commercialization of its lead product candidate.
Founded in 2016 and headquartered in New York, New York, Applied Therapeutics is committed to advancing its pipeline and bringing innovative treatments to patients in need. For more information, please visit their website at https://www.appliedtherapeutics.com.
Drawdown (Underwater) Chart
Overall Trend and Yearly Seasonality
APLT Stock Overview
Market Cap in USD | 1,030m |
Sector | Healthcare |
Industry | Biotechnology |
GiC SubIndustry | Biotechnology |
TER | 0.00% |
IPO / Inception | 2019-05-14 |
APLT Stock Ratings
Growth 5y | -35.2 |
Fundamental | - |
Dividend | |
Rel. Performance vs Sector | 9.55 |
Analysts | 4.83/5 |
Fair Price Momentum | 12.35 USD |
Fair Price DCF | - |
APLT Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | 0.00% |
Dividends CAGR 5y | 0.00% |
Payout Consistency | 0.0% |
APLT Growth Ratios
Growth Correlation 3m | 72.8% |
Growth Correlation 12m | 76.9% |
Growth Correlation 5y | -68.1% |
CAGR 5y | -12.16% |
CAGR/Mean DD 5y | -0.16 |
Sharpe Ratio 12m | 1.51 |
Alpha vs SP500 12m | 194.94 |
Beta vs SP500 5y weekly | 1.23 |
ValueRay RSI | 68.40 |
Volatility GJR Garch 1y | 102.28% |
Price / SMA 50 | 19.36% |
Price / SMA 200 | 57.48% |
Current Volume | 681.1k |
Average Volume 20d | 1709k |
External Links for APLT Stock
Wall Street Journal • Benzinga • Yahoo Finance
Tweets
X • Stocktwits
Fund Manager Positions
Dataroma • Stockcircle
As of October 29, 2024, the stock is trading at USD 8.63 with a total of 681,107 shares traded.
Over the past week, the price has changed by -4.00%, over one month by +4.35%, over three months by +71.23% and over the past year by +259.58%.
According to ValueRays Forecast Model, APLT Applied Therapeutics will be worth about 13.8 in October 2025. The stock is currently trading at 8.63. This means that the stock has a potential upside of +59.91%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 12.8 | 48.3 |
Analysts Target Price | 7.7 | -11.1 |
ValueRay Target Price | 13.8 | 59.9 |